Stephens Investment Management Group LLC Has $69.82 Million Position in Icon Plc (ICLR)
Stephens Investment Management Group LLC decreased its position in Icon Plc (NASDAQ:ICLR) by 1.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 713,960 shares of the medical research company’s stock after selling 10,522 shares during the period. Icon Plc makes up approximately 1.7% of Stephens Investment Management Group LLC’s holdings, making the stock its 2nd biggest position. Stephens Investment Management Group LLC owned 1.32% of Icon Plc worth $69,818,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in ICLR. Shine Investment Advisory Services Inc. bought a new position in Icon Plc in the 2nd quarter worth about $103,000. Parallel Advisors LLC boosted its stake in Icon Plc by 20.7% in the 2nd quarter. Parallel Advisors LLC now owns 1,265 shares of the medical research company’s stock worth $133,000 after purchasing an additional 217 shares in the last quarter. US Bancorp DE boosted its stake in Icon Plc by 15.0% in the 1st quarter. US Bancorp DE now owns 1,929 shares of the medical research company’s stock worth $154,000 after purchasing an additional 251 shares in the last quarter. Huntington National Bank boosted its stake in Icon Plc by 5.0% in the 2nd quarter. Huntington National Bank now owns 1,630 shares of the medical research company’s stock worth $159,000 after purchasing an additional 77 shares in the last quarter. Finally, Quantbot Technologies LP boosted its stake in Icon Plc by 40.9% in the 1st quarter. Quantbot Technologies LP now owns 2,022 shares of the medical research company’s stock worth $161,000 after purchasing an additional 587 shares in the last quarter. Institutional investors own 90.62% of the company’s stock.
A number of equities analysts recently issued reports on the stock. Zacks Investment Research cut shares of Icon Plc from a “buy” rating to a “hold” rating in a research note on Thursday. Bank of America Corporation assumed coverage on shares of Icon Plc in a research note on Monday. They issued a “buy” rating and a $128.00 price target on the stock. ValuEngine upgraded shares of Icon Plc from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. Credit Suisse Group reiterated a “buy” rating on shares of Icon Plc in a research note on Friday, July 28th. Finally, BidaskClub upgraded shares of Icon Plc from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 22nd. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $113.11.
WARNING: “Stephens Investment Management Group LLC Has $69.82 Million Position in Icon Plc (ICLR)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/11/stephens-investment-management-group-llc-has-69-82-million-position-in-icon-plc-iclr.html.
Icon Plc (NASDAQ ICLR) traded up 0.57% during trading on Monday, reaching $115.76. 105,980 shares of the company’s stock traded hands. The firm has a market cap of $6.26 billion, a price-to-earnings ratio of 23.48 and a beta of 0.61. The company has a 50 day moving average of $106.59 and a 200 day moving average of $92.52. Icon Plc has a one year low of $73.76 and a one year high of $117.53.
Icon Plc (NASDAQ:ICLR) last released its quarterly earnings data on Thursday, July 27th. The medical research company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.01. Icon Plc had a return on equity of 28.72% and a net margin of 15.97%. The business had revenue of $431 million for the quarter, compared to the consensus estimate of $430.68 million. During the same quarter in the prior year, the business posted $1.14 EPS. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. Equities research analysts predict that Icon Plc will post $5.32 EPS for the current year.
Icon Plc Profile
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Stock Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related stocks with our FREE daily email newsletter.